secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biomea Fusion, Inc. (BMEA)
CIK:        0001840439
Form:       8-K
Filed at:   2022-09-23T23:59:59+00:00
Accession:  0001193125-22-249373
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biomea Fusion EASD data: BMF-219 increases beta cell mass in human islets, improves glycemic control in rat T2D models
--------------------------------------------------------------------------------

- BMF-219 increased beta cell mass in ex vivo human donor islets, first such translational data presented.
- In ZDF rats, OGTT AUC reduced 54% vs vehicle (p<0.001) during treatment; 40% reduction maintained 2 weeks after washout (p<0.05).
- In STZ rats, BMF-219 nearly doubled HOMA-B (+96%) and restored non-fasting glucose to near-normal by day 8.
- BMF-219 reduced blood lipemic levels and body weight in both ZDF and STZ rat models.
- Company remains on track to file IND for BMF-219 in type 2 diabetes in second half of 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1840439/000119312522249373/0001193125-22-249373-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1840439/000119312522249373/d397871d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-249373

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer